Loading…

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Saved in:

Bibliographic Details
Published in:	Blood 2022-11, Vol.140 (Supplement 1), p.3753-3755
Main Authors:	Budde, Elizabeth L., Bartlett, Nancy L., Giri, Pratyush, Schuster, Stephen J., Assouline, Sarit, Yoon, Sung-Soo, Fay, Keith, Matasar, Matthew J., Gutierrez, Norma C., Marlton, Paula, Dreyling, Martin, Yoon, Dok Hyun, Hess, Georg, Radford, John, Wiebking, Volker, Yin, Shen, Cybulski, Eva, Turner, David C., Huang, Huang, Zhou, Mingzhu, Penuel, Elicia, Wei, Michael C., Sehn, Laurie H.
Format:	Article
Language:	English
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!